Rapid communication · 29 May 2025
Conference abstractPublished 2016
Early diagnosis, incretin-based therapies and gene therapy approaches for type 2 diabetes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
It has now become obvious that the pathophysiological defects leading to type 2 diabetes (T2D) is much more complex than thought before. Insulin resistance is an early event in the course of T2D development. The transition from normoglycemy to pre-diabetes is usually a gradual phenomenon that occurs over 5-10 years during which the disease remains undetected. Among the routinely practiced T2D screening criteria, like, FPG, IFG, IGT or HbA1c, still the issue of a preferable one is debated. Here I present more precise noninvasive pre-symptomatic diagnosis and risk assessment strategies including non-coding RNAs signature in peripheral blood. Life style changes with addition of metformin, sulphonylureas, glinides, α-glucosidase inhibitors, thiazolidinediones and/ or exogenous insulin are recommended as the present treatment options. These treatments offer improvement in glycemic control, but in many instances produce significant adverse side effects. Various novel incretin-based therapies like prolonging GLP-1 receptor agonists action, orally GLP-1 receptor agonists, GLP-1 secretion by activating GLP-1-producing intestinal L-cells, synthetic engineered peptides as co-agonists stimulating more than one receptor, etc. are discussed here. I also present our experiences regarding development of successful gene therapy using intestinal K-cells which are specialized for GIP production. Engineering these cells to produce insulin in response to the ingested carbohydrates successfully achieved. Oral gene delivery to these cells using nanoparticles with appropriate protective coats as well as plant exosomal gene delivery to the stem cell precursors of K-cells located at the base of intestinal crypts resulted in long lasting insulin expression by gut K-cells and pronounced treatment of T2D.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Rasoul Salehi”
- BylineArticles whose byline prints “Ahmad Raza Salehi”
- BylineArticles whose byline prints “Nasimeh Vatandoust”
- BylineArticles whose byline prints “Sedigheh Momenzadeh”